RespireRx

From WikiMD's Wellness Encyclopedia

RespireRx (formerly known as Cortex Pharmaceuticals) is a biopharmaceutical company that focuses on the discovery and development of drugs for the treatment of neurological and psychiatric disorders. The company's primary focus is on the development of drugs that modulate the activity of specific neurotransmitters in the brain.

History[edit | edit source]

RespireRx was originally founded as Cortex Pharmaceuticals in 1987. The company changed its name to RespireRx in 2015 to reflect its new focus on the development of drugs for the treatment of respiratory disorders, including sleep apnea and opioid-induced respiratory depression.

Research and Development[edit | edit source]

RespireRx's research and development efforts are focused on two main areas: the modulation of the GABA (gamma-aminobutyric acid) system and the modulation of the glutamate system. The company's GABA-related research is focused on the development of drugs that can enhance the activity of GABA, the primary inhibitory neurotransmitter in the brain. This research has led to the development of a number of potential drugs, including dronabinol, a synthetic form of cannabinoid that is currently in Phase II clinical trials for the treatment of sleep apnea.

The company's glutamate-related research is focused on the development of drugs that can inhibit the activity of glutamate, the primary excitatory neurotransmitter in the brain. This research has led to the development of ampakines, a class of drugs that can enhance the activity of the AMPA receptor, a type of glutamate receptor. Ampakines are currently in preclinical development for the treatment of a variety of neurological and psychiatric disorders, including schizophrenia, depression, and Alzheimer's disease.

Financials[edit | edit source]

As a publicly traded company, RespireRx is required to disclose its financial information to the public. The company's financial reports can be found on its website and on the website of the U.S. Securities and Exchange Commission.

See Also[edit | edit source]


This biopharmaceutical related article is a stub. You can help WikiMD by expanding it.

Contributors: Prab R. Tumpati, MD